Skip to content
Full Committee Hearing

“Valeant Pharmaceuticals' Business Model: the Repercussions for Patients and the Health Care System”

Date:
Time: 03:30pm
Location: Hart, Room 216

Panel I

  • Berna Heyman

    Wilson Disease patient, and retired Associate Dean of Libraries
    William & Mary
  • Dr. Frederick K. Askari, M.D. PhD

    Associate Professor, and Director, Wilson Disease Center of Excellence
    University of Michigan Health System
  • Dr. Richard Fogel M.D., FACC, FHRS

    Chief Clinical Officer
    St. Vincent

Panel II

  • William A. Ackman

    Founder and Chief Executive Officer, Director,
    Pershing Square Capitol Management LP,, Valeant Pharmaceuticals International, Inc.,
  • J. Michael Pearson

    Chief Executive Officer
    Valeant Pharmaceuticals International, Inc
  • Howard Schiller

    Director, former Chief Financial Officer, and former Interim Chief Executive Officer
    Valeant Pharmaceuticals International, Inc.,